Shanghai InnoStar Bio-tech (688710.SH) passes U.S. FDA on-site inspection
Shanghai InnoStar Bio-tech (688710.SH) announced that during 2026, the company underwent a comprehensive on-site Good Laboratory Practice (GLP) inspection by the U.S. Food and Drug Administration (FDA).
Shanghai InnoStar Bio-tech (688710.SH) announced that during 2026, the company underwent a comprehensive on-site inspection for Good Laboratory Practice (GLP) by the U.S. Food and Drug Administration ("FDA"). Recently, the company received the Establishment Inspection Report (EIR) issued by the FDA, which indicates that based on the requirements of U.S. 21 CFR regulations (Title 21 of the U.S. Code of Federal Regulations), the FDA has confirmed that this inspection has been closed. The letter indicates that the company complies with the FDA's Good Laboratory Practice (GLP) regulations, that the information submitted to the FDA is scientific and reliable, and that it successfully passed this FDA unannounced inspection, with the inspection result being Voluntary Action Indicated (VAI).
Related Articles

MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.
MS CONCEPT (08447) announces interim results, with a net loss of HK$1.521 million.

Zijin Mining Group (02899) plans to repurchase RMB2 billion to RMB3 billion of its A-shares.

US Stock Market Move | NVIDIA Corporation (NVDA.US) rose 4%; institutions believe the stock price has already priced in the risk of leadership changes.






